| Ovarian cancer group (n = 225) | Breast and ovarian cancer group (n = 64) |
---|---|---|
Mean age at ovarian cancer diagnosis in years (range) | 48.8 (16.9-70.6) | 51.2 (33.8-66.9) |
Mean age at breast cancer diagnosis in years (range) | Â | 48.1 (25.0-72.9) |
BRCA1 mutation status | Â | Â |
• Negative | 198 (88.0%) | 46 (71.9%) |
• Positive | 27 (12.0%) | 18 (28.1%) |
BRCA1 mutation type | Â | Â |
• 5382insC (c.5266dupC) | 17 (63.0%) | 14 (77.8%) |
• 300 T/G (c.181 T > G) | 8 (29.6%) | 2 (11.1%) |
• 185delAG (c.68-69delAG) | 2 (7.4%) | 2 (11.1%) |
• 4153delA (c. 4034delA) | -- | -- |
• 3819del5 (c.3700_3704del5) | -- | -- |
Ovarian Cancer | ||
FIGO | Â | Â |
• I | 73 (32.4%) | 16 (25.0%) |
• II | 33 (14.7%) | 5 (7.8%) |
• III | 95 (42.2%) | 31 (48.5%) |
• IV | 13 (5.8%) | 2 (3.1%) |
• Unspecified/unknown | 11 (4.9%) | 10 (15.6%) |
GRADE | Â | Â |
• G1- well differentiated | 34 (15.1%) | 3 (4.7%) |
• G2- moderately differentiated | 98 (43.6%) | 20 (31.2%) |
• G3- undifferentiated | 86 (38.2%) | 29 (45.3%) |
• G4 | 1 (0.4%) | -- |
• unspecified/unknown | 6 (2.7) | 12 (18.8%) |
Histology | Â | Â |
• Serous | 121 (53.8%) | 41 (64.1%) |
• Mucinous | 23 (10.2%) | 2 (3.1%) |
• Endometrioid | 33 (14.7%) | 2 (3.1%) |
• Clear cell | 6 (2.7%) | 1 (1.6%) |
• Other/unspecified | 41 (18.2%) | 15 (23.4%) |
• Unknown | 1 (0.4%) | 3 (4.7%) |
Breast Cancer | ||
GRADE | Â | Â |
• G1- well differentiated |  | 10 (15.6%) |
• G2- moderately differentiated |  | 22 (34.4%) |
• G3- undifferentiated |  | 6 (9.4%) |
• Unspecified/unknown |  | 26 (40.6%) |
Histology | Â | Â |
• Ductal carcinoma in situ |  | 1 (1.6%) |
• Ductal carcinoma |  | 44 (68.7%) |
• Lobular carcinoma |  | 1 (1.6%) |
• Medullary carcinoma |  | 3 (4.7%) |
• Other |  | 13 (20.3%) |
• Unspecified |  | 2 (3.1%) |